Contact Information:
zxmei@txccc.org
832-824-4175

---

Education:
M.D. Guangzhou Medical College, Guangzhou, China

Research Interests:
Manufacture of clinical grade viral vectors, monoclonal antibodies and plasmid DNA

Selected Publications:
S. Takahashi; P. Yotnda; R.F. Rousseau; Z. Mei; S. Smith; D. Rill; A. Younes; M.K. Brenner Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin’s lymphoma. Cancer Gene Therapy 2001; 8:378-387

Satoshi Takahashi; Raphael F. Rousseau; Patricia Yotnda; Zhuyong Mei; Gianpietro Dotti ; Donna Rill; Richard Hurwitz; Frank Marini; Michael Andreeff; Malcolm K. Brenner Autologous Antileukemic Immune response Induced by Chronic Lymphocytic Leukemia B Cells Expressing the CD40 Ligand and interleukin 2 Transgenes. Human Gene Therapy 2001; 12:659-670

Raphael F. Rousseau; Ann E. Haight; Charlotte Hirschmann-Jax; Eric S. Yvon; Donna R. Rill; Zhuyong Mei; Susan C. Smith; Shannon Inman; Kristine Cooper; Pat Alcoser; Bambi Grilley; Adrian Gee; Edwina Popek; Andrew Davidoff; Laura C. Bowman; Malcolm K. Brenner; Douglas Strother Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2002; 101:1718-1726

Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man., Ann N Y Acad Sci. 2003 May;996:80-8.

Krance RA, Kuehnle I, Rill DR, Mei Z, Pinetta C, Evans W, Brown MP, Pule M, Heslop HE, Brenner MK., Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4): 273-81.

R.F. Rousseau; E. Biagi; A.Dutour; E.S. Yvon; M.P. Brown; T. Lin; Z. Mei; B.Grilley; E.Popek; H.E. Heslop; A.P. Gee; R.A. Krance; U.Popat; G.Carrum; J.F. Margolin; M.K. Brenner: Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332- 1341. Epub 2005 Oct 25.

Russell, HV; Strother, D; Mei, Z; Rill, DR; Popek, E; Biagi, E; Yvon, E; Brenner, MK; Rousseau,RF: Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin. Journal of Immunotherapy. 30(2):227-233, February/March 2007